Evidence map›Paper›PMID 29508177›Full record

Observational studyClinical rheumatology2018

Anti-adalimumab antibodies in a cohort of patients with juvenile idiopathic arthritis: incidence and clinical correlations.

Achille Marino, Feliciana Real-Fernández, Paolo Rovero, Teresa Giani, Ilaria Pagnini, Rolando Cimaz, Gabriele Simonini

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Biotherapies in Uveitis.Journal of clinical medicine · 2020
    Review
  11. Review
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Achille MarinoDepartment of Neurosciences, Psychology, Drug Research and Child Health, Rheumatology Unit, Meyer Children's Hospital, University of Florence, Viale Gaetano Pieraccini 24, 50139, Florence, Italy. achillemarino6@gmail.com.
Feliciana Real-FernándezDepartment of Neurosciences, Psychology, Drug Research and Child Health - Section of Pharmaceutical Sciences and Nutraceutics - Interdepartmental Laboratory of Peptide and Protein Chemistry and Biology (PeptLab), University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Italy.
Paolo RoveroDepartment of Neurosciences, Psychology, Drug Research and Child Health - Section of Pharmaceutical Sciences and Nutraceutics - Interdepartmental Laboratory of Peptide and Protein Chemistry and Biology (PeptLab), University of Florence, Via Ugo Schiff 6, 50019, Sesto Fiorentino, Italy.
Teresa GianiRheumatology Unit, Meyer Children's Hospital, University of Florence, Viale Gaetano Pieraccini 24, 50139, Florence, Italy.
Ilaria PagniniRheumatology Unit, Meyer Children's Hospital, University of Florence, Viale Gaetano Pieraccini 24, 50139, Florence, Italy.
Rolando CimazDepartment of Neurosciences, Psychology, Drug Research and Child Health, Rheumatology Unit, Meyer Children's Hospital, University of Florence, Viale Gaetano Pieraccini 24, 50139, Florence, Italy.
Gabriele SimoniniDepartment of Neurosciences, Psychology, Drug Research and Child Health, Rheumatology Unit, Meyer Children's Hospital, University of Florence, Viale Gaetano Pieraccini 24, 50139, Florence, Italy.
University of Florence · ITMeyer Children's Hospital · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adalimumab is a TNF-α blocker antibody similar in structure and function to natural human IgG1. Even if adalimumab is fully humanized, the development of anti-drug antibodies has been reported in several inflammatory conditions. The objective of our study was to assess the presence of anti-adalimumab antibodies (AAA) and their clinical relevance in a cohort of juvenile idiopathic arthritis (JIA) patients on adalimumab. This is a prospective observational cohort study recruiting JIA children. Experiments were performed using a validated surface plasmon resonance (SPR)-based optical assay (Biacore® T100). Disease activity was evaluated using the Juvenile Arthritis Disease Activity Score with 10 joint count (JADAS-10). The Mann-Whitney U test, Wilcoxon signed-rank test for paired samples, chi-square, and Fisher exact test were used to compare data. Pearson's and Spearman's correlation tests were used to determine correlation coefficients for entered variables: demographic, clinical, and serological data. Ten (37%) out of 27 patients included in the study had at least one AAA-positive sample. Patients developed AAA between 3 and 38 months after starting adalimumab. Seven (70%) out of 10 children with AAA positivity experienced at least a relapse compared to 4 (23.5%) out of 17 AAA-negative children (r

Indexed as

Antibodies, Anti-IdiotypicAdalimumabAdolescentAntibodies, Monoclonal, HumanizedArthritis, JuvenileChildChild, PreschoolCombined Modality TherapyFemaleHumansMaleMethotrexateProspective StudiesTreatment OutcomeAdalimumabAntibodies, Anti-IdiotypicAntibodies, Monoclonal, HumanizedMethotrexateAdalimumabImmunogenicityJIASurface plasmon resonance

Identifiers

PMID29508177
OpenAlexW2792302810

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.